Anne Wojcicki regains control of 23andMe, the company she co-founded and led as CEO, through her nonprofit TTAM with a $305 million bid at a bankruptcy auction.

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s ...

23andMe co-founder and former CEO Anne Wojcicki is set to buy back the company after it filed for Chapter 11 bankruptcy protection earlier this year. On Friday, 23andMe and TTAM Research Institute ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe's co-founder ...

In a surprise twist, 23andMe founder and former CEO Anne Wojcicki is set to regain control of the DNA company's assets, according to a press release from 23andMe. In May, a company called ...

Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron ...

More than 11 million customers have given DNA samples to 23andMe, putting a trove of genetic information under the company’s control. Wojcicki’s nonprofit TTAM Research Institute agreed to ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction.

Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.

Former 23andMe CEO Anne Wojcicki is set to regain control of the genetic testing firm she led to bankruptcy after outbidding a pharmaceutical company at an auction. The sale came on Monday after a ...

23andMe co-founder and former CEO Anne Wojcicki is set to buy back the company through a nonprofit public benefit corporation, TTAM Research Institute.

In a surprise twist, 23andMe founder and former CEO Anne Wojcicki is set to regain control of the DNA company's assets, according to a press release from 23andMe.